Health & Fitness
Health and Fitness
Health and Fitness
Tue, March 19, 2013Mon, March 18, 2013Sun, March 17, 2013Fri, March 15, 2013Thu, March 14, 2013Wed, March 13, 2013Tue, March 12, 2013Mon, March 11, 2013Sun, March 10, 2013Sat, March 9, 2013Fri, March 8, 2013Thu, March 7, 2013Wed, March 6, 2013Tue, March 5, 2013Mon, March 4, 2013Sun, March 3, 2013Sat, March 2, 2013Fri, March 1, 2013Thu, February 28, 2013Wed, February 27, 2013Tue, February 26, 2013Mon, February 25, 2013Sun, February 24, 2013Sat, February 23, 2013Fri, February 22, 2013Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Published in Health and Fitness on Tuesday, March 5th 2013 at 13:30 GMT by Market Wire
Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference -- SAN DIEGO, March 5, 2013 /PRNewswire/ --
SAN DIEGO, March 5, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: [ HALO ]) will be presenting at the Barclays 2013 Global Healthcare Conference in Miami, FL. on March 12, 2013 at 4:15 p.m. ET/1:15 p.m. PT. Kurt Gustafson , Chief Financial Officer of Halozyme Therapeutics, will provide a corporate overview.
(Logo: [ http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ])
The presentation will be webcast through the "Investors" section of Halozyme's corporate website at [ www.halozyme.com ], and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at [ www.halozyme.com ].
Investor Contact:
Kurt Gustafson
Halozyme Therapeutics
858-704-8272
[ ir@halozyme.com ]
Media Contact:
Nurha Hindi
Hill + Knowlton Strategies
310-633-9434
[ Nurha.Hindi@hkstrategies.com ]
SOURCE Halozyme Therapeutics, Inc.
RELATED LINKS
[ http://www.halozyme.com ]
